文献速递胸部肿瘤放疗

T0状态对不可切除III期非小细胞肺癌总生存的影响:NCDB分析

Role of T0 status in overall survival for unresectable stage III non-small cell lung cancer: A NCDB analysis.
PubMed 文献 · Radiother Oncol · 2020-03-26

基于NCDB数据库回顾性分析2004-2016年不可切除III期NSCLC接受放疗未手术患者,比较T0与T1-4组生存。T0组458例,T1-4组84263例。T0状态与更年轻、近期诊断、腺癌、N3期及化疗使用相关,总生存显著优于T1-4组(p<0.0001),5年OS率30.5% vs 12.7%,化疗组33.6% vs 14.6%,倾向评分匹配及SEER独立分析验证。

要点

  • 不可切除III期NSCLC中T0状态与显著延长的总生存相关(p<0.0001)。
  • T0组5年OS率为30.5%,T1-4组为12.7%;化疗组分别为33.6%和14.6%。
  • T0状态与更年轻、近期诊断、腺癌、N3期及化疗使用相关。

核心结论

  • 在不可切除III期NSCLC接受放疗未手术的患者中,T0状态提示有利预后。
  • 研究者建议未来研究可将T0状态视为独立分期(如IIC期)。

研究设计与样本

  • 基于美国国家癌症数据库(NCDB)的回顾性队列分析,纳入2004-2016年接受放疗未手术的N2-3M0 NSCLC病例。
  • T0组458例,T1-4组84263例;采用Kaplan-Meier、log-rank检验及Cox比例风险模型进行生存分析,并行倾向评分匹配及SEER独立验证。

主要发现

  • T0状态与更年轻年龄、近期诊断(2010-2016年)、腺癌组织学、N3期及化疗使用相关。
  • T0组总生存显著优于T1-4组(p<0.0001),总体人群5年OS率30.5% vs 12.7%,化疗组33.6% vs 14.6%。
  • 倾向评分匹配后总生存差异仍显著(p<0.0001),SEER独立分析证实该发现。

关键数值与推荐

  • T0组5年总生存率30.5%,T1-4组12.7%(总体人群)。
  • 化疗组T0与T1-4的5年总生存率分别为33.6%和14.6%。

临床怎么用

  • 对不可切除III期NSCLC伴T0状态者,可考虑将其作为预后较好亚组进行个体化治疗决策。
  • T0状态患者接受化疗的比例较高,生存获益在化疗组中同样显著。

局限性

  • 回顾性数据库研究,存在选择偏倚可能,已用倾向评分匹配及SEER验证部分控制。
  • T0组样本量相对较小(458例),需前瞻性研究进一步确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Occult primary non-small cell lung cancer (NSCLC) with mediastinal involvement is a known but rare clinical condition. Very limited retrospective data are available in the literature. Its prognosis and response to systemic chemotherapy have not been investigated with large scale data. MATERIALS AND METHODS: Using National Cancer Database (NCDB), cases that had undergone radiation therapy without surgery for N2-3M0 NSCLC were selected. Demographics and survival data were compared between T0 and T1-4 groups. Survival analyses were conducted with Kaplan-Meier and log-rank tests. Cox proportional hazard models were used for univariate and multivariate analyses. RESULTS: Between 2004 and 2016, 84,263 and 458 cases met criteria for unresectable stage III NSCLC with T1-4 and T0 stage, respectively. T0 status was associated with younger age, recent diagnosis (year 2010-2016), adenocarcinoma histology, N3 stage, and use of chemotherapy. Survival analysis demonstrated that those with T0 status had prolonged overall survival as compared to T1-4 counterparts in both overall and chemotherapy groups (p < 0.0001 for each). Five-year overall survival rates for T0 and T1-4 groups were 30.5% and 12.7% in all groups, and 33.6% and 14.6% in chemotherapy groups, respectively. Propensity score matching also demonstrated a statistically significant difference in overall survival (p < 0.0001). These findings are confirmed by independent analysis using Surveillance, Epidemiology, and End Results Program (SEER). CONCLUSION: This large hospital-based study demonstrates the favorable prognosis for T0 status in the setting of unresectable stage III NSCLC. Researchers may consider it as distinct stage (e.g., stage IIC) for future studies.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Komiya T, Powell E, Vu CC, et al. Role of T0 status in overall survival for unresectable stage III non-small cell lung cancer: A NCDB analysis. Radiother Oncol. 2020. PMID: 32294582. doi:10.1016/j.radonc.2020.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。